No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer By Ogkologos - August 19, 2025 517 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ASTER 70s study Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR ESMO Highlights Key Issues for Patients with Cancer and Their Carers... May 27, 2025 FDA Approves Idecabtagene Vicleucel for Multiple Myeloma April 7, 2021 EMA Recommends Granting a Conditional Marketing Authorisation for Repotrectinib November 27, 2024 Early Signs of Efficacy of New Targeted Agents and Immunotherapies Reported... September 24, 2021 Load more HOT NEWS Advancing Patient Care Through Focused Innovation Garbage Men Finally Meet Cancer-Free Toddler After Bonding From Afar ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to... How to Provide Support as a Long-Distance Cancer Caregiver
